{"title":"使用 FAERS 研究 2 型糖尿病患者服用抗糖尿病药物导致阿尔茨海默病的风险。","authors":"Hayato Akimoto, Akio Negishi, Shinji Oshima, Haruna Wakiyama, Mitsuyoshi Okita, Norimitsu Horii, Naoko Inoue, Shigeru Ohshima, Daisuke Kobayashi","doi":"10.1177/1533317519899546","DOIUrl":null,"url":null,"abstract":"<p><p>Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We compared the risk of AD among 66 085 patients (≥ 65 years) with T2DM (1250 having concomitant AD) who had been administered antidiabetic drug monotherapy for T2DM who had voluntarily reported themselves in the Food and Drug Administration Adverse Event Reporting System. The risk of AD from the use of different antidiabetic drug monotherapies compared to that of metformin monotherapy was assessed by logistic regression. Rosiglitazone (adjusted reporting odds ratio [aROR] = 0.11; 95% confidence interval [CI]: 0.07-0.17; <i>P</i> < .001), exenatide (aROR = 0.22; 95% CI: 0.11-0.37; <i>P</i> < .001), liraglutide (aROR = 0.36; 95% CI: 0.19-0.62; <i>P</i> < .001), dulaglutide (aROR = 0.39; 95% CI: 0.17-0.77; <i>P</i> = .014), and sitagliptin (aROR = 0.75; 95% CI: 0.60-0.93; <i>P</i> = .011) were found to have a significantly lower associated risk of AD than that of metformin. Therefore, the administration of glucagon-like peptide 1 receptor agonists and rosiglitazone may reduce the risk of AD in patients with T2DM.</p>","PeriodicalId":50816,"journal":{"name":"American Journal of Alzheimers Disease and Other Dementias","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11005324/pdf/","citationCount":"0","resultStr":"{\"title\":\"Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS.\",\"authors\":\"Hayato Akimoto, Akio Negishi, Shinji Oshima, Haruna Wakiyama, Mitsuyoshi Okita, Norimitsu Horii, Naoko Inoue, Shigeru Ohshima, Daisuke Kobayashi\",\"doi\":\"10.1177/1533317519899546\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We compared the risk of AD among 66 085 patients (≥ 65 years) with T2DM (1250 having concomitant AD) who had been administered antidiabetic drug monotherapy for T2DM who had voluntarily reported themselves in the Food and Drug Administration Adverse Event Reporting System. The risk of AD from the use of different antidiabetic drug monotherapies compared to that of metformin monotherapy was assessed by logistic regression. Rosiglitazone (adjusted reporting odds ratio [aROR] = 0.11; 95% confidence interval [CI]: 0.07-0.17; <i>P</i> < .001), exenatide (aROR = 0.22; 95% CI: 0.11-0.37; <i>P</i> < .001), liraglutide (aROR = 0.36; 95% CI: 0.19-0.62; <i>P</i> < .001), dulaglutide (aROR = 0.39; 95% CI: 0.17-0.77; <i>P</i> = .014), and sitagliptin (aROR = 0.75; 95% CI: 0.60-0.93; <i>P</i> = .011) were found to have a significantly lower associated risk of AD than that of metformin. Therefore, the administration of glucagon-like peptide 1 receptor agonists and rosiglitazone may reduce the risk of AD in patients with T2DM.</p>\",\"PeriodicalId\":50816,\"journal\":{\"name\":\"American Journal of Alzheimers Disease and Other Dementias\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11005324/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Alzheimers Disease and Other Dementias\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/1533317519899546\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Alzheimers Disease and Other Dementias","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1533317519899546","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
阿尔茨海默病(AD)可能在 2 型糖尿病(T2DM)发病后出现,而阿尔茨海默病的风险可能取决于所使用的抗糖尿病药物。我们比较了 66 085 名 T2DM 患者(≥ 65 岁)(其中 1250 人同时患有 AD)的 AD 风险,这些患者曾接受过 T2DM 抗糖尿病药物单药治疗,并自愿在食品药品管理局不良事件报告系统中进行了自我报告。通过逻辑回归评估了与二甲双胍单药治疗相比,使用不同抗糖尿病药物单药治疗并发急性肾衰竭的风险。罗格列酮(调整后的报告几率比 [aROR] = 0.11; 95% 置信区间 [CI]:0.07-0.17; P < .001)、艾塞那肽(aROR = 0.22; 95% CI: 0.11-0.37; P < .001)、利拉鲁肽(aROR = 0.36; 95% CI: 0.19-0.62; P < .001)、度拉鲁肽(aROR = 0.39; 95% CI: 0.17-0.77; P = .014)和西他列汀(aROR = 0.75; 95% CI: 0.60-0.93; P = .011)的AD相关风险显著低于二甲双胍。因此,服用胰高血糖素样肽1受体激动剂和罗格列酮可降低T2DM患者罹患AD的风险。
Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS.
Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We compared the risk of AD among 66 085 patients (≥ 65 years) with T2DM (1250 having concomitant AD) who had been administered antidiabetic drug monotherapy for T2DM who had voluntarily reported themselves in the Food and Drug Administration Adverse Event Reporting System. The risk of AD from the use of different antidiabetic drug monotherapies compared to that of metformin monotherapy was assessed by logistic regression. Rosiglitazone (adjusted reporting odds ratio [aROR] = 0.11; 95% confidence interval [CI]: 0.07-0.17; P < .001), exenatide (aROR = 0.22; 95% CI: 0.11-0.37; P < .001), liraglutide (aROR = 0.36; 95% CI: 0.19-0.62; P < .001), dulaglutide (aROR = 0.39; 95% CI: 0.17-0.77; P = .014), and sitagliptin (aROR = 0.75; 95% CI: 0.60-0.93; P = .011) were found to have a significantly lower associated risk of AD than that of metformin. Therefore, the administration of glucagon-like peptide 1 receptor agonists and rosiglitazone may reduce the risk of AD in patients with T2DM.
期刊介绍:
American Journal of Alzheimer''s Disease and other Dementias® (AJADD) is for professionals on the frontlines of Alzheimer''s care, dementia, and clinical depression--especially physicians, nurses, psychiatrists, administrators, and other healthcare specialists who manage patients with dementias and their families. This journal is a member of the Committee on Publication Ethics (COPE).